Company profile for HMNC Brain Health

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HMNC Brain Health defines the future of depression and anxiety treatment: We develop innovative personalized therapies to shorten the duration of treatment, improve treatment outcomes and reduce the risk of relapse.Our portfolio includes laboratory tests that help to optimize treatment with antidepressants on the market, as well as innovative medicines against depression and anxiety. Our innovative methods are supported by lab...
HMNC Brain Health defines the future of depression and anxiety treatment: We develop innovative personalized therapies to shorten the duration of treatment, improve treatment outcomes and reduce the risk of relapse.Our portfolio includes laboratory tests that help to optimize treatment with antidepressants on the market, as well as innovative medicines against depression and anxiety. Our innovative methods are supported by laboratory diagnostics and help to recommend the right medication to the patient more quickly.The development of such antidepressants and the accompanying diagnostics are the focus of HMNC.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Wilhelm-Wagenfeld-Straße 20 D-80807 München
Telephone
Telephone
+49 (0)89 - 360 90 200
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/15/3167316/0/en/Ketabon-Presents-New-Data-Showing-Antidepressant-Effects-of-Oral-Ketamine-KET01-Are-Independent-of-Dissociation.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/10/13/3165474/0/en/HMNC-Brain-Health-Presents-New-Analysis-Supporting-Rationale-for-Combining-a-Genetic-Patient-Selection-Tool-with-a-Vasopressin-V1b-Receptor-Antagonist-in-the-Treatment-of-Depressio.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/08/05/3127402/0/en/HMNC-Brain-Health-Announces-Phase-2-Results-from-OLIVE-Trial-in-Major-Depressive-Disorder-MDD-with-Genetically-Guided-Precision-Approach.html

GLOBENEWSWIRE
05 Aug 2025

https://www.fiercebiotech.com/biotech/hmnc-recalibrates-precision-depression-push-after-phase-2b-miss-plans-further-development

FIERCE BIOTECH
05 Aug 2025

https://www.globenewswire.com/news-release/2025/01/10/3007736/0/en/HMNC-Brain-Health-Completes-Patient-Randomization-for-Phase-2b-OLIVE-Trial-for-Major-Depressive-Disorder.html

GLOBENEWSWIRE
10 Jan 2025

https://www.globenewswire.com/news-release/2024/12/11/2995266/0/en/HMNC-Brain-Health-Collaborates-with-the-Austrian-Institute-of-Technology-and-the-Danube-Private-University-to-Win-Grant-from-the-Austrian-Research-Promotion-Agency.html

GLOBENEWSWIRE
11 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty